SADIF Analytics releases new summary due diligence report for Sirtex Medical Limited

www.sadifanalytics.com

2009-11-25 01:14:23 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Sirtex Medical Limited and produced a report, rating the company's attractiveness to long-term investors.

Ilhavo, Portugal – 25/11/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Sirtex Medical Limited (SRX). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Sirtex Medical Limited investor.

Report Summary: Sirtex Medical Limited is an above average quality company with a neutral outlook. Sirtex Medical Limited has

strong business growth and is run by efficient management. When compared to its closest peer, Antisense Therapeutics Limited, Sirtex Medical Limited shows similar overvaluation and is more likely to outperform the market.

The 8-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Sirtex Medical Limited for long-term investors.

The report has been distributed to Reuters, and forwarded to Yahoo Finance and FT.com. It is available under 'Analyst Reports' from these websites, from multiple professional platforms including Reuters Knowledge, TheMarkets.com, Thomson Research and Capital IQ or directly from SADIF-Investment Analytics at:
www.sadifanalytics.com/stockmarks/company.php?tickerr=SRX&cod_co ..

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 12,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.